Antibody fragments produced by bacterial fermentation lack natural effector functions. Bispecific antibody fragments, however, can be endowed with effector functions, for example cell-mediated killing, by binding to and retargeting of cytotoxic cells. Diabodies are a class of engineered antibody fragments with two antigen binding sites, consisting of two associated chains; each chain consists of heavy and light chain variable domains linked by a short polypeptide linker. In contrast to IgG, or other antibody fragments in which the two binding sites can take up a range of orientations and spacings, the diabody structure is more rigid and compact, with the two binding sites separated by 65 A fless than half the distance in IgG). To establish whether diabodies could also be used in cellmediated killing, we have explored the use of a bispecific diabody binding to an idiotypic marker on mouse B-cell lymphoma (BCL-1) and to mouse CD3. The bispecific diabody activated naive T-cells and also mediated the specific killing of the lymphoma cells by cytotoxic T-cells. The diabody was less active in T-cell activation but 10-fold more active (w/v) in killing than an analogous bispecific IgG.
Introduction
Bispecific antibodies (bisAbs) allow the crosslinking of two different antigens, and can therefore be used to trigger cellmediated killing, for example by bridging a cell surface antigen on a tumour cell with the CD-T-cell receptor complex on a cytotoxic T-cell (Liu et al, 1985; Staerz and Bevan, 1986) . Despite their potential as therapeutic agents, few bisAbs have made it into clinical evaluation mainly because of difficulties in producing bisAbs in sufficient quantity and purity. Several different approaches have been used to make bisAbs, for example by chemical coupling of two different antibodies (Karpovsky et al, 1984) or by fusion of two different hybridomas (Milstein and Cuello, 1983) . However, both procedures usually result in complex product mixtures from which the bisAb must be isolated.
Recently, the use of protein engineering has permitted entirely new designs for bisAbs, based on antigen-binding fragments [such as single-chain Fv (scFv) fragments] as building blocks rather than whole antibodies [for review, see Holliger and Winter, 1993) ]. In scFv fragments, the VH and VL domains are associated non-covalently and also linked by a flexible polypeptide between the N-terminus of one domain and the C-terminus of the other; bispecific scFv fragments (biscFv) can be created by linking two scFv fragments together on the same polypeptide chain to give a four-domain structure. Such biscFv fragments are flexible (Mallender et al, 1994) , and are capable of binding to two adjacent epitopes on the same antigen (Neri et al, 1995) or of crosslinking antigens on two different cells to mediate cell lysis (Kurucz et al, 1995; Mack et al, 1995) .
An alternative bispecific antibody fragment is the diabody (Holliger et al, 1993) . Instead of a single polypeptide chain with four domains, diabodies are dimers, each chain consisting of two domains. Each chain consists of a VH domain connected to a VL domain using a linker that is too short to allow pairing between domains on the same chain. This promotes pairing between complementary domains of another chain and thereby creates two binding sites. Thus for a bispecific diabody (made from antibodies A and B), the first chain is assembled from the VH domain of antibody A and the VL domain of antibody B (and the second chain from the VH domain of antibody B and the VL domain of antibody A). Co-expression of the two chains (VHA-VLB, VHB-VLA) leads to assembly of bispecific diabodies.
In diabodies the antigen-binding sites are at opposite ends of the molecule, as predicted by computer graphic modelling (Holliger et al, 1993) and shown by X-ray crystallography (Perisic et al, 1994) . However, compared with bisAbs or biscFv fragments, diabodies are expected to be more compact and less flexible owing to the use of two short linkers to connect the two antigen-binding sites.
Here we have investigated whether these constraints allow diabodies to be used to crosslink cells. We prepared a bispecific diabody directed against the mouse CD3-T-cell receptor complex and the surface idiotype of the mouse lymphoma line BCL-1. The diabody was tested for its ability to crosslink mouse T-cells to lymphoma cells and also to induce killing of the lymphoma cells by cytotoxic T-cells in vitro.
Materials and methods

Vector construction
Escherichia coli TGI (Gibson, 1984) was used for propagation of plasmids and expression of antibody fragments (see Figure 1 for details of construction). Bl was first recloned from the scFv (De Jonge et al, 1995) as a bivalent diabody with a five amino acid linker (GGGGS) between VH and VL from the scFv. The VHB1 was amplified with primers 1-2, the VLB1 with the primers 3 and the primer mix 4 (Clackson et al, 1991) . In the process a SacI restriction site was introduced at the N-terminus of the VL domain changing residues 3 and 4 of VL from Val-Met to Glu-Leu. The VH-B1 PCR fragment was digested with Sfil and BstEII, the VL-B1 PCR fragment with NotI and BstEII and both fragments simultaneously ligated into Sfil/NotI digested pUC119His6myc [pUC119SNmyc (Clackson et al, 1991) with His6 tag].
145.2C11 is a hamster hybridoma secreting a monoclonal antibody specific for mouse CD3 T-cell co-receptor e chain (Leo et aL, 1987) . cDNA was prepared using a First Strand cDNA synthesis kit (Pharmacia) and random pd(N) 6 primer mix. VH and VL gene segments were PCR amplified using Pfu polymerase (Stratagene) from cDNA using primer pairs 5 and 6 (VH), and primer 7 and primer mix 8 (VL) (Clackson et aL, 1991) . VH2C11 was reamplified with the primers 9 and 6, VL 2C11 was reamplified with the primer 10 and the primer mix 4 (Clackson et aL, 1991) using Taq polymerase and digested with Sfil and BstEH (VH), and Nod and BstEH (VL). The fragments were cloned as above into Sfil/NotI digested pUC119SfiNotmyc (Clackson et aL, 1991) .
Construction of the bispecific diabody B1/2C11 was essentially as described (Holliger et aL, 1993) . VH 2C11 was amplified using primers 11 and 12 and VL 2C11 with primers 10 and 13 and the VH 2C11 was digested with AscI and Sad, and VL 2C11 with AscI and BstEH A vector fragment of diabody Bl (see above) was cut with BstEII/SacI and cut vector dephosphorylated using calf intestinal phosphatase (CIP) (Boehringer Mannheim). The VH and VL 2C11 were ligated with pUC119-Bl/5. Ligation mixes, transformation and sequencing were as described (Holliger et aL, 1993) .
Oligonucleotides
Primer 1, 5'-CAT GCC ACT CGC GGC CCA GCC GGC CAT GGC CGA AGT GAA GCT GGT GGA GTC TGG-3'; primer 2, 5'-CAG ATC TGA GGA GAC GGT GAC CGT GGT CCC TGC GCC CC-3'; primer 3, 5'-GAG CCA TCA ATC GAT CTG GTC ACC GTC TCC TCA GGC GGT GGC GGA TCG GAC ATT GAG CTC ACC CAG TCT CAA-3'; primer 4, VK4FORNOT mix (Clackson et aL, 1991) ; primer 5, 5'-CSA GGT YCA RCT GCA GCA GYC TGG-3'; primer 6, VH1FOR-2 (Orlandi et aL, 1989); primer 7, 5'-GAC ATT GTG CTR ACC CAR TCT CCA; primer 8, VK4FOR mix (Clackson et aL, 1991) ; primer 9, 5'-CAT GCC ATG ACT CGC GGC CCA GCC GGC CAT GGC CGA GGT GCA GCT GGT GGA GTC TGG-3'; primer 10, 5'-GAG CCA TCA ATC GAT CTG GTC ACC GTC TCC TCA GGC GGT GGC GGA TCT GAC ATC CAG ATG ACC CAG TCT CCA-3'; primer 11, 5'-GAG TCA TTC TCG ACT CTG TCG GGC GCG CCT CAT GAT TAC GCC CAG CTT GCA TGC-3' ; primer 12, 5'-GAG CCA TCA ATC TCG GAG CTC GAT GTC CGA TCC GCC ACC GCC TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC CC-3'; primer 13, 5'-GAC TCA TTC TCG ACT GAG CTC ACT TGG CGC GCC TTA TTA CCG TTT GAT CTC GAG CTT GGT CCC-3'.
Expression
Soluble diabody was prepared from periplasmic lysates (Breitling et aL, 1991; Skerra and PlUckthun, 1988) and from bacterial supernatants (Better et aL, 1988) . ELISA was performed as described (Ward et aL, 1989) except for using BCL-1 IgM as antigen coated at a concentration of 1 |J.g/ml in PBS at 4°C overnight and blocking the plate with 3% BSA-PBS for 2 h at room temperature. Large-scale culture of diabodies was performed as above except that after induction the cells were shaken for 24 h at 22°C. The cells were then pelleted and the culture supernatant was filtered, concentrated and dialysed against three changes of PBS using a FTLTRON Minisette. Imobilized metal affinity chromatographic (IMAC) purification of His 6 -tagged bispecific diabody B1/2C11 was as described (Hochuli et at., 1988) . IMAC-purified B1/2C11 diabody was further affinity purified on an IgM BCL1 Sepharose column [prepared from CNBr-activated Sepharose (Pharmacia) and BCL-1 IgM according to the manufacturer's instructions]. Protein was eluted from the column with 3.5 M MgCl 2 and dialysed extensively against Tris-buffered saline (TBS) and then PBS. FACScan Target cells (e.g. EL-4) were spun down at 1200 rpm at 4°C for 5 min and washed twice in ice-cold PBSBA (PBS-1% BSA-0.05% NaN 3 ), then 10 5 cells per incubation in 50 ul of PBSBA in Cell Wells (Costar) were incubated with 50 \i\ of periplasmic lysate or culture supernatant for 30 min at 4°C. Cells were pelleted with a quick spin at 2000 rpm for 2 min and supernatant aspirated. For detection (using the c-myc tag), the cells were resuspended with 9E10 hybridoma culture supernatant diluted 1:100 in PBSBA and incubated for 30 min at 4°C. Cells were pelleted as above and supernatant aspirated. Cells were then resuspended with fluorescein-labelled antimouse serum (Fab2 fragment) (Sigma) 1:120 in PBSBA and incubated for 30 min at 4°C in the dark. Cells were pelleted as above and supernatant aspirated and cells washed twice in 1 ml of PBSBA and resuspended in a final volume of 1 ml of PBSBA.then transferred into clear 6 ml tubes (Falcon). Flow cytometry was carried out with a Becton and Dickinson FACScan.
Activation of naive T-cells and cytotoxic T-cell assay
Activation of T-cells was performed as described by Brissinck et al. (1991) . BALB/c-derived BCL-1 lymphoma cells were washed extensively in RPMI and then incubated with mitomycin C (25 ug/ml) (Sigma) for 90 min in the dark at 37°C. After extensive washing to remove excess mitomycin C, the tumour cells were plated into tissue culture-treated CellWells (round bottomed) (Costar) at 5X10 5 cells/well in triplicate and co-cultured in RPMI-10% fetal calf serum (FCS) with 10 5 syngeneic splenocytes in the presence or absence of bispecific diabody. T-cells were also enriched from whole spleen cell population by non-adherence to nylon wool columns as described (Julius et aL, 1973) . After 64 h the cells were pulsed with 3 H-labelled thymidine (0.5 uCi) (Amersham) for 8 h before harvesting. Incorporated counts were measured in a beta scintillation counter (Wallach). The same assay was also performed with sterile BCL-1 IgM Id coated on to tissue culture-treated CellWells (round bottomed) (Costar) at a concentration of 10 |i.g/ml in PBS. After extensive washing to remove unbound antibody, splenocytes were added and processed as above.
Cellular cytotoxicity of T-cells was performed as described (Brissinck et aL, 1991) . Primary alloreactive cytotoxic T-cells (CTLs) were generated as follows: splenic responder cells (BALB/c) were co-cultured for 5 days with an equal number of irradiated (5000 rad) stimulator cells (C57BL/6) in RPMI-10% supplemented with 10% (v/v) supernatant of rat spleen cell culture activated by Concavalin A (Sigma).
BCL-1 tumour cells were loaded with 5l Cr by incubating 3X10 6 cells with 150 ^Ci of Na 2 51 CrO 4 (Amersham) in 250 ^1 of culture medium and 50 nl of FCS for 1 h at 37°C. The labelled cells were washed until no radioactivity was detectable in the wash (3-4 times) before use. Effector (CTLs) and target cells (BCL-1) were added to round-bottomed CellWells in triplicate at various effectortarget ratios (from 100:1 to 12.5:1) and a final volume of 200 ul The 51 Cr release from BCL-1 cells was measured in a standard 4 h assay in the presence or absence of bispecific diabody. Counts released to the supemat-ant were measured in a gamma counter (Wallach). The percentage specific lysis was calculated as (f 
Modelling of diabody flexibility
To estimate the extent of flexibility of one Fv head relative to the other in a diabody, a model of one Fv head of diabody L5MK16 (Perisic et al., 1994) was used. Our objective was to fix one Fv head and place a second one in all possible orientations relative to the first and test which relative positions would be feasible given the length of the linker between the two Fv heads in the diabody. After fixing the position of one Fv head, a finite set of orientations of the second was generated as follows: a vector r of length IH was constructed with its 'tail' at the centroid of the first Fv head with an orientation described by the spherical coordinates (<)), xf). A rotational symmetry axis, s, was then generated in the plane containing the 'head' of r and perpendicular to r. The orientation of s in the plane can be described by the angle K. A second Fv was generated by rotating the first Fv around the axis s by an angle y. The second Fv was then translated away from the first Fv along the axis r until there were no atoms overlapping between the two Fvs. This final position of the second Fv was accepted as a plausible position if the distance between the beginnings and the ends of the linkers were within a preset upper and lower bounds, L^ and L,. The search for acceptable second Fv positions was carried out with $ and \y varying from 0° to 360° in 10° increments and with K and y from 0° to 180° in 10° increments. The value of IH was 19.5 A (half of the distance between the centroids of the two Fv heads in the experimentally determined structure of L5MK16). L\ and Lŵ ere 5 and 24 A, respectively.
Results
We cloned the VH and VL genes for the hamster anti-mouse CD3 antibody 2C11 from the hybridoma as a bivalent diabody for expression in E.coli (Figure 1 ). Crude periplasmic lysates of the 2C11 diabody bound to mouse T-cell lines (EL-4, MD90) as shown by fluorescence-activated cell sorting (FACS) (not shown). The VH and VL genes for the anti-BCL-1 idiotype (anti-Id) scFv B1 were recloned likewise as a bivalent diabody (Figure 1 ). Crude periplasmic lysates of the Bl diabody bound to BCL-1 as shown by ELJSA using the BCL-1 IgM protein and FACS using BCL-1 lymphoma cells. No binding could be detected by FACS to a related mouse lymphoma (A20) or to a mouse T-cell line (EL-4) (not shown).
We then built the B1/2C11 bispecific diabody (Figure 1 ..CGG TAA TAA ggcgcgcctcatgattacgcccagcttgcatgcaaanctamcaaggagacagtcauATG AAA Fig. 1 . Construction of the bispecific diabody B1/2C11. The variable domains genes of the hamster anti-mouse CD3 antibody 2C11 (VHC, V1X) were PCR amplified from the hybridoma and cloned as diabody (five residue linker) into a pUC-derived expression vector (pUC 119SNpolymyc) (Clackson et al., 1991) under the control of the lac promoter (P), with lacZ ribosome binding site (rbsl) and the pelB leader sequence (Ll) for secretion to the periplasm (Ward et aL, 1989) . Likewise, the variable domains genes of the mouse anti-BCLl Id antibody Bl (VHB, VLB) were recloned as a five linker diabody into^the vector pUCI 19His6myc and a SacI site was introduced at the 5' end of the VL segment. B1 and 2CI1 were then recombined to create a bispecific diabody. Locations of PCR primers 1-4, 6 and 9-11 are shown. and isolated the protein from the culture supernatant by IMAC using a C-terminal His 6 tag, with a yield of 2.5 mg/1. The diabody could be further purified by gel filtration on a Sepharose S-200 column (Pharmacia), and emerged mainly as a peak of about 50 kDa, with a minor peak of about 100 kDa (presumably corresponding to the diabody dimer). Alternatively, the diabody could be purified by affinity chromatography on a BCL-1-Id-IgM Sepharose column. Both preparations had similar cytotoxic activities when compared at different effector: target ratios ( Figure 4B ) or in a dose-response curve (not shown) (see below and Materials and methods). The bispecific diabody was shown to bind to BCL-1 by ELJSA and FACS (as above); no binding could be detected by FACS to the A20 cell line. The diabody was also shown by FACS to bind to mouse CD3 + T-cell lines [EL-4, MD90 (not shown)] but not to a CD3" mouse fibroblast line (L929) (not shown) (Figure 2 ). Surface expression of CD3 was verified by binding of an anti-mouse CD3 IgG labelled with FTTC (Serotech).
The bispecific diabody induced strong activation and proliferation of naive T-cells (of a splenocyte preparation) in the presence of BCL-1 lymphoma cells, as shown by [ 3 H]thymidine incorporation into DNA (Figure 3) . The same results were obtained with splenocytes in which the T-cells had been enriched to about 90% by non-adherence to nylon wool columns (not shown). The activation of T-cells was specific: no proliferation was seen when splenocytes and lymphoma cells were incubated without the bispecific diabody (not shown) or when diabody was incubated with either splenocytes or lymphoma cells alone (not shown). No proliferation was seen when another related lymphoma line (A20) was used as target cell (Figure 3 ) or when the bivalent Bl diabody was used instead of the bispecific B1/2C11 diabody (not shown). Further, proliferation could be inhibited by soluble IgG B1 (Figure 3) . . At 4 ng/ml the diabody showed a specific lysis of 40%. For comparison the cytotoxicity of the hybrid-hybridoma B1X7D6 is also shown (filled squares). (B) T-cell cytotoxicity measured at a fixed bisAb concentration (25 ng/ml) at different effectortarget ratios. Maximal specific lysis was typically between 70 and 80% measured after 4 h for a targetxffector ratio of 1:50, dropping to 50-60% when the target:effector ratio was decreased to 12.5:1. Comparable specific lysis was obtained for two different preparations of the diabody prepared by 1MAC (open squares) and by BCL-1 Id affinity chromatography (open diamonds).
40% lysis at 4 ng/ml ( Figure 4A ). No lysis of lymphoma cells was seen in the absence of diabody or CTLs, or when the lymphoma A20 was used as target cell. Lysis was inhibited by mAb B1 in a dose-dependent manner (not shown).
The B1/2C11 diabody was compared with a related hybridhybridoma B1X7D6 prepared by double affinity chromatography as described (Brissinck et al, 1991) . B1X7D6 is also directed against BCL 1 and CD3, but comprises the mouse anti-CD3 antibody (7D6) rather than the hamster anti-CD3 (2C11). The B1/2C11 diabody proved threefold less potent in activation (not shown), but 10-fold more potent at cell lysis (w/v) ( Figure 4A ). In cell lysis, the increased potency of the diabody in relation to the B1X7D6 hybrid-hybridoma was independent of the effectortarget ratio. (Perisic et al, 1994) drawn using the program GRASP (Nicholls et al., 1992) in red or blue to differentiate the two chains of the diabody. The large gold sphere marks the position of Ca of residue Y105 in the middle of the H3 loop. The green spheres mark the cluster of positions of Y105 on one Fv head that are mapped out by varying the orientation of this head with respect to the other. The loci of acceptable positions are defined as follows: for each acceptable position, i, a vector q was constructed from the point midway between positions represented by the gold spheres to the position marked by a green sphere. The mean of these vectors, c^,, was used as a reference vector to calculate an angle 8 angle between <;", and q. The mean angle 9 between Fv heads was 28° with a standard deviation of 14°. The observed H3 midpoint (gold sphere) had an angle 9 of 34*. The maximum deviation from the mean vector was 66°.
Discussion
Bispecific antibodies have been used previously to mediate the killing of target cells by crosslinking a cell-surface antigen on the target cell and either the T-cell co-receptor (CD3) on cytotoxic T-cells or the Fc receptor IE (CD 16) on NK-cells. (Liu et al, 1985; Staerz and Bevan, 1986) . To induce activation it appears that the effector and target cells must be bound simultaneously to one another (Roosnek and Lanzaveccia, 1989) , and that the bispecific antibody must therefore bridge the two cells.
To investigate the ability of a bispecific diabody to crosslink cytotoxic T-cells to target cells and mediate cell lysis, we chose the murine B-cell lymphoma BCL-1 as a target (Slavin and Strober, 1978; George et al, 1988) . In several respects the tumour resembles non-Hodgkin's lymphoma, and bispecific antibodies (hybrid-hybridoma) had already been used for immunotherapy of BCL-1 lymphoma in immunocompetent syngeneic mice (Brissinck et al, 1991) . We constructed a bispecific diabody using an antibody directed against the idiotype of the BCL-1 lymphoma surface immunoglobulin (Bl) as the targeting specificity and an antibody binding with high affinity to mouse CD3 (2C11) as the effector specificity.
The bispecific diabody, expressed in E.coli and purified in a single step, was able to crosslink naive T-cells to the target cells as judged by activation of the T-cells. It was also able to induce preactivated cytotoxic T-cells to kill the target cells efficiently. The potency of the diabody (w/v) in the T-cell activation and the cytotoxicity assay appears to be comparable to a (refolded) biscFv comprising the same antibody V-genes Bl and 2C11 (De Jonge et al, 1995) . We were also able to make a comparison with an analogous hybrid-hybridoma bispecific antibody B1X7D6 (Brissinck et al, 1991 ) that employs another anti-CD3 antibody (7D6) as the effector specificity. This revealed that the diabody was less potent at activating naive T-cells but more potent in recruiting activated T-cells for cytolysis of the target cells.
The differences in behaviour between diabody and hybrid hybridoma could reflect, inter alia, different affinities for the T-cell receptor or the use of different epitopes thereon. Activation of naive T-cells may also profit from the presence of the Fc portion of the hybrid-hybridoma. Fc receptors are present both on lymphoma cells and certain types of T-cells (reviewed by Sandor and Lynch, 1993) . Engagement of the Fc by its cognate receptors may induce increased avidity binding and/or provide a co-stimulatory signal to the T-cell (Beun et al, 1993) . This is consistent with results from another anti-lymphoma Id (38C13)Xanti-CD3 (2C11) hybridhybridoma which was compared with its Fab'2 fragment. The Fab'2 fragment was significantly less active in the activation of naive T-cells both in vitro and in vivo (Weiner et al, 1994) . However, in another study (Demanet et al, 1991) using the same lymphoma model (38C13) the Fc portion did not appear to contribute to the potency of the bisAb.
By contrast, the increased potency of the diabody in cytolysis may be due to the bringing of the T-cells into closer proximity to the target cell. When we attempted to model the flexibility and distance constraints of the diabody design using the structure of a bivalent diabody (Perisics et al, 1994 ) with a five amino acid (Gly4Ser) linker between the VH and VL domains, we found the distance between two antigen binding sites to vary between 69 and 43 A ( Figure 5) . Recently, the complete structure of an intact canine IgG (including the hinge region) was solved at 3.5 A resolution (Harris et al, 1992) . In that structure the span between the centres of the two antigen binding sites (Tyr 99) measures 147 A (L.Harris, personal communication), but may reach up to 170 A with fully outstretched Fab arms. Diabodies therefore reach less than half the span of an IgG and simultaneous engagement of BCL-1 surface Ig and TCR should bring the T-cells closer to the target cells. Further, while the model suggests that the diabody is able to adopt a range of different conformations, most flexibility lies in a direction perpendicular to the line between the centres of the two Fvs ( Figure 5 ). Acceptable conformations cluster within 30° of the mean of allowed conformations. Although the IgG structure of Harris et al. (1992) does not give any information on limits of the flexibility of Fab arms, they assume an asymmetric orientation in relation to the oblique Fc portion, indicating a fairly loose tethering function of the hinge region. Hence one may safely assume that diabodies are significantly more rigid. It is tempting to speculate that this rigidity also should lead to a more stable crosslinking of T-cells and target cells owing to entropic factors, but these may be dissipated by the flexibility of the two antigens and membrane fluidity.
As the cytolytic machinery of cytotoxic T-cells appears to involve local exocytosis of a cytotoxic cocktail at the cellcell contact interface (reviewed by Apasov et al. (1993) , we suggest that a tighter effector-target cell interface may lead to a higher local concentration of the cocktail and thereby to increased cytolysis.
Diabodies represent an attractive format for engineered bispecific antibodies. They are similar in size to Fab fragments and this should facilitate penetration of tumours and clearance from the serum (Yokota et al, 1992) . Diabodies are simple to construct and can be expressed by secretion from bacterial cultures in contrast to the (single-chain) biscFv fragments, which in general have been refolded from inclusion bodies (George et al, 1994) , or expressed in mammalian cells (Traunecker et al, 1992) . The two chains spontaneously assemble in vivo, in contrast to the larger bispecific Fab2 fragments that have to be crosslinked in vitro (Brennan et al, 1985; Carter et al, 1992) and diabodies are readily isolated by a single round of affinity chromatography, in contrast to hybrid-hybridomas. The demonstration that diabodies are capable of mediating effector functions illustrates their potential as therapeutic agents.
